GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Net Income Including Noncontrolling Interests

Lumos Diagnostics Holdings (ASX:LDX) Net Income Including Noncontrolling Interests : A$-7.71 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Lumos Diagnostics Holdings's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2024 was A$-4.43 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 was A$-7.71 Mil.

Lumos Diagnostics Holdings Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Lumos Diagnostics Holdings's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Net Income Including Noncontrolling Interests Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24
Net Income Including Noncontrolling Interests
-65.07 -13.37 -12.94

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial -9.73 -3.59 -9.58 -3.28 -4.43

Lumos Diagnostics Holdings Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-7.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ASX:CDX ASX:NTI ASX:OSL ASX:UBI ASX:AT1 ASX:HMD ASX:CBL ASX:EYE ASX:CVB ASX:IRX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM STE PODD
Traded in Other Exchanges
LDXHF:USA
Address
2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Website
https://www.lumosdiagnostics.com
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.

Lumos Diagnostics Holdings Headlines

No Headlines